Mirati Therapeutics (NASDAQ:MRTX) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Get Free Report) in a report released on Monday. The firm set a “sell” rating on the biotechnology company’s stock. MRTX has been the topic of a number of other reports. Stifel Nicolaus reaffirmed a “hold” rating and issued a $59.00 price […]

Related Keywords

United States ,Jamie Christensen ,Benjamin Hickey ,Leerink Partnrs ,Stifel Nicolaus ,Acadian Asset Management ,Citigroup ,Headlands Technologies ,Mirati Therapeutics Inc ,Bluepath Capital Management ,Nasdaq ,First Horizon Advisors Inc ,Securities Exchange Commission ,Mirati Therapeutics ,Get Free Report ,Exchange Commission ,Horizon Advisors ,Asset Management ,Path Capital Management ,Mirati Therapeutics Daily ,Nasdaq Mrtx ,Mrtx ,Medical ,Initiated Coverage ,Stocknews Com ,